Xiao Bingxin, Sun Zengxian, Cao Fangrui, Wang Lisha, Liao Yonghong, Liu Xinmin, Pan Ruile, Chang Qi
Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China.
Department of Clinical Pharmacology, The First People's Hospital of LianyungangLianyungang, China.
Front Pharmacol. 2017 Sep 5;8:599. doi: 10.3389/fphar.2017.00599. eCollection 2017.
Isoflavonoids are putatively active components of and has been demonstrated prominent neuro-protection effect against cerebrovascular disorders, hypertension or Parkinson's disease (PD). However, the molecular basis for the beneficial effect of on nervous systems has not been well revealed. The present study aims to assess striatum exposure to main active isoflavonoids and changes of striatal extracellular neurotransmitters levels in rat brain after intravenous administration of isoflavonoids extracts (PLF), to further elucidate its' substantial bases for neuro activities. Fifteen rats were divided into 3 groups (five rats in each group) to receive a dose of PLF at 80 or 160 mg/kg or normal saline (vehicle), respectively. An LC-MS/MS method was employed to determine the concentrations of five main isoflavonoids and multiple neurotransmitters in microdialysate from striatal extracellular fluid (ECF) of the rats. The exposed quantities of puerarin (PU), 3'-methoxypuerarin (MPU), daidzein-8-C-apiosyl-(1-6)-glucoside (DAC), and 3'-hydroxypuerarin (HPU) in striatum were dose-dependent. The content of daidzein (DAZ) was too low to be detected in all dialysate samples through the experiment. Optimal dose PLF (80 mg/kg) promoted DA metabolism and inhibited 5-HT metabolism. No obvious change in the level of GLu was determined. The concentration of GABA presented a temporary decline firstly and then a gradual uptrend followed by a further downtrend. Higher dose (160 mg/kg) PLF could enhance the metabolism of both DA and 5-HT, and lower the extracellular level of GLu, without changing GABA concentrations, which might result in alleviation on excitatory toxicity under conditions, such as ischemia. The results infer that different dose of PLF should be chosen to achieve appropriate neurochemical modulation effects under conditions, such as hypertension or ischemia/stroke. These findings may significantly contribute to a better understanding of the neuroprotective effect of and provide new insights into its application toward neuro-degenerative diseases in the future.
异黄酮被认为是[某种物质]的活性成分,并且已被证明对脑血管疾病、高血压或帕金森病(PD)具有显著的神经保护作用。然而,[该物质]对神经系统有益作用的分子基础尚未得到充分揭示。本研究旨在评估静脉注射异黄酮提取物(PLF)后大鼠脑内纹状体对主要活性异黄酮的暴露情况以及纹状体细胞外神经递质水平的变化,以进一步阐明其神经活性的实质基础。将15只大鼠分为3组(每组5只),分别接受80或160mg/kg的PLF剂量或生理盐水(溶剂)。采用液相色谱-串联质谱法(LC-MS/MS)测定大鼠纹状体细胞外液(ECF)微透析液中五种主要异黄酮和多种神经递质的浓度。纹状体中葛根素(PU)、3'-甲氧基葛根素(MPU)、大豆苷元-8-C-芹菜糖基-(1-6)-葡萄糖苷(DAC)和3'-羟基葛根素(HPU)的暴露量呈剂量依赖性。通过实验,在所有透析液样品中大豆苷元(DAZ)的含量过低而无法检测到。最佳剂量的PLF(80mg/kg)促进多巴胺(DA)代谢并抑制5-羟色胺(5-HT)代谢。未测定到谷氨酸(GLu)水平有明显变化。γ-氨基丁酸(GABA)的浓度首先呈现暂时下降,然后逐渐上升,随后进一步下降。更高剂量(160mg/kg)的PLF可增强DA和5-HT的代谢,并降低细胞外GLu水平,而不改变GABA浓度,这可能在诸如缺血等情况下减轻兴奋性毒性。结果表明,在高血压或缺血/中风等情况下,应选择不同剂量的PLF以实现适当的神经化学调节作用。这些发现可能有助于更好地理解[该物质]的神经保护作用,并为其未来在神经退行性疾病中的应用提供新的见解。